Figure 3
MRC-depleted BCR-ABL1 leukemia cells display reduced ROS and oxidative DNA damage. (A-D) BCR-ABL1-32Dcl3 cells expressing nonmutated BCR-ABL1 kinase (nm) and indicated TKI-resistant (TKIR) mutants and CD34+ cells from CML-CP patients (control cells, gray bars) were depleted of mtDNA (Rho0 cells, white bars). (A) Expression of Cox II and GADPH mRNA by RT-PCR. ROS were detected by DCFDA (B) and 8-oxoG (C) and γ-H2AX (D) foci were analyzed by immunofluorescence. (E) ROS were detected by DCFDA in 32Dcl3 cells expressing TEL-ABL1 (T/A), TEL-JAK2 (T/J), and TEL-PDGFβR (T/P; gray bars) and in corresponding Rho0 cells (white bars). Results represent mean values ± SD from a minimum of 2 experiments/group (A,B,E) and from 25-55 cells/group (C-D). *P < .05 compared with control cells.

MRC-depleted BCR-ABL1 leukemia cells display reduced ROS and oxidative DNA damage. (A-D) BCR-ABL1-32Dcl3 cells expressing nonmutated BCR-ABL1 kinase (nm) and indicated TKI-resistant (TKIR) mutants and CD34+ cells from CML-CP patients (control cells, gray bars) were depleted of mtDNA (Rho0 cells, white bars). (A) Expression of Cox II and GADPH mRNA by RT-PCR. ROS were detected by DCFDA (B) and 8-oxoG (C) and γ-H2AX (D) foci were analyzed by immunofluorescence. (E) ROS were detected by DCFDA in 32Dcl3 cells expressing TEL-ABL1 (T/A), TEL-JAK2 (T/J), and TEL-PDGFβR (T/P; gray bars) and in corresponding Rho0 cells (white bars). Results represent mean values ± SD from a minimum of 2 experiments/group (A,B,E) and from 25-55 cells/group (C-D). *P < .05 compared with control cells.

Close Modal

or Create an Account

Close Modal
Close Modal